⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301549 | 0.92 | EPHX2 (0.32) | — | |
| SCHEMBL17301550 | 0.88 | PIM1 (0.31) | — | |
| SCHEMBL17304925 | 0.88 | BCHE (0.31) | — | |
| SCHEMBL17190379 | 0.86 | CCNE1 (0.30) | — | |
| SCHEMBL17190386 | 0.85 | — | — | |
| SCHEMBL17301536 | 0.85 | — | — | |
| SCHEMBL17190381 | 0.84 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL23016169 | 0.84 | CYP3A4 (0.34) | — | |
| SCHEMBL20017263 | 0.83 | — | — | |
| SCHEMBL23436601 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-20210162060-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-06-03 | — | — | US | disclosed |
| US-10967069-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-04-06 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-01-07 | — | — | US | disclosed |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-10004810-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-9931408-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2018-04-03 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |